# cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study

> **NCT03243604** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 1717 (actual)

## Conditions studied

- Arrhythmias, Cardiac
- Atrial Fibrillation and Flutter
- Tachycardia, Supraventricular
- Cardiac Failure

## Interventions

- **DRUG:** L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)

## Key facts

- **NCT ID:** NCT03243604
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-16
- **Primary completion:** 2017-07-13
- **Final completion:** 2017-07-13
- **Target enrollment:** 1717 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03243604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03243604, "cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03243604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*